# Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

> **NCT04620473** · PHASE2 · WITHDRAWN · sponsor: **Shanghai Minimally Invasive Surgery Center**

## Conditions studied

- Neoadjuvant Treatment
- Rectal Cancer
- Anlotinib

## Interventions

- **DRUG:** Anlotinib+Capeox
- **DRUG:** Capeox

## Key facts

- **NCT ID:** NCT04620473
- **Lead sponsor:** Shanghai Minimally Invasive Surgery Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-11-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No approval from ethical committee
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620473, "Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04620473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*